Annals of Clinical and Translational Neurology (May 2021)
Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis
- Audrey Gauthier,
- Sébastien Viel,
- Magali Perret,
- Guillaume Brocard,
- Romain Casey,
- Christine Lombard,
- Sabine Laurent‐Chabalier,
- Marc Debouverie,
- Gilles Edan,
- Sandra Vukusic,
- Christine Lebrun‐Frénay,
- Jérôme De Sèze,
- David Axel Laplaud,
- Giovanni Castelnovo,
- Olivier Gout,
- Aurélie Ruet,
- Thibault Moreau,
- Olivier Casez,
- Pierre Clavelou,
- Eric Berger,
- Hélène Zephir,
- Sophie Trouillet‐Assant,
- Eric Thouvenot,
- OFSEP Investigators
Affiliations
- Audrey Gauthier
- Paris Sciences et Lettres ‐ École Pratique des Hautes Études Paris France
- Sébastien Viel
- Immunology laboratory Hospices Civils de LyonLyon Sud Hospital Pierre‐Bénite France
- Magali Perret
- Immunology laboratory Hospices Civils de LyonLyon Sud Hospital Pierre‐Bénite France
- Guillaume Brocard
- Université de LyonUniversité Claude Bernard Lyon 1 LyonF‐69000France
- Romain Casey
- Université de LyonUniversité Claude Bernard Lyon 1 LyonF‐69000France
- Christine Lombard
- Immunology laboratory Hospices Civils de LyonLyon Sud Hospital Pierre‐Bénite France
- Sabine Laurent‐Chabalier
- Department of Biostatistics Clinical Epidemiology, Public Health, and Innovation in Methodology CHU NîmesUniv. Montpellier Nîmes France
- Marc Debouverie
- Department of Neurology Nancy University Hospital Nancy France
- Gilles Edan
- CHU Pontchaillou RennesCIC1414 INSERM, F‐35000France
- Sandra Vukusic
- Université de LyonUniversité Claude Bernard Lyon 1 LyonF‐69000France
- Christine Lebrun‐Frénay
- Department of Neurology UR2CA URRIS CRCSEP Centre Hospitalier Universitaire Pasteur2 Université Nice Côte d'Azur Nice France
- Jérôme De Sèze
- Department of Neurology and Clinical Investigation Center CIC 1434, INSERM 1434 CHU de Strasbourg StrasbourgF‐67000France
- David Axel Laplaud
- Department of Neurology and CIC015 INSERM CHU de Nantes NantesF‐44093France
- Giovanni Castelnovo
- Department of Neurology CHU NîmesUniv Montpellier Nîmes France
- Olivier Gout
- Department of Neurology Fondation Rothschild ParisF‐75000France
- Aurélie Ruet
- Univ. Bordeaux BordeauxF‐33000France
- Thibault Moreau
- Department of Neurology CHU de DijonEA4184 DijonF‐21000France
- Olivier Casez
- Department of Neurology CHU Grenoble Alpes La Tronche/GrenobleF‐38700France
- Pierre Clavelou
- Department of Neurology CHU Clermont‐Ferrand Clermont‐FerrandF‐63000France
- Eric Berger
- Department of Neurology CHU Besançon BesançonF‐25030France
- Hélène Zephir
- CHU LilleCRCSEP LilleUniv Lille LilleU1172, F‐59000France
- Sophie Trouillet‐Assant
- International Center of Research in Infectiology Lyon UniversityINSERM U1111CNRS UMR 5308ENSUCBL Lyon France
- Eric Thouvenot
- Department of Neurology CHU NîmesUniv Montpellier Nîmes France
- OFSEP Investigators
- DOI
- https://doi.org/10.1002/acn3.51355
- Journal volume & issue
-
Vol. 8,
no. 5
pp. 1141 – 1150
Abstract
Abstract We compared SimoaTM and EllaTM immunoassays to assess serum neurofilament‐light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The EllaTM instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to EllaTM results. As for SimoaTM, serum neurofilament‐light chain levels measured by EllaTM were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.